AZD 8186

Drug Profile

AZD 8186

Alternative Names: AZD-8186

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 29 Nov 2016 Interim efficacy, adverse event, pharmacokinetic and pharmacodynamic data from a phase I trial in Prostate cancer, Non-small cell lung cancer, Breast cancer and Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 24 Apr 2015 AstraZeneca and Janssen agree to co-develop combination of AZD-8186 and Abiraterone acetate for Prostate cancer
  • 24 Apr 2015 AstraZeneca and Janssen plans a phase-I/IIa trial for Prostate cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top